As a long-term degenerative disorder of the central nervous system that mostly affects older
people, Parkinson's disease is a growing health threat to our ever-aging population. Despite …

Parkinson's disease is a highly disabling, progressive neurodegenerative disease that
manifests as a mix of motor and non‐motor signs. Although we are equipped with some …

The development of an intervention to slow or halt disease progression remains the greatest
unmet therapeutic need in Parkinson's disease. Given the number of failures of various …

The pursuit of approved drugs and unapproved drug candidates repurposing for novel
clinical applications is an attractive strategy due to its speed and high efficiency. Most …

Given the high whittling down rates, high costs, and moderate pace of new medication,
revelation, and improvement, repurposing “old” drugs to treat typical and uncommon …

The international Linked Clinical Trials (iLCT) program for Parkinson's to date represents
one of the most comprehensive drug repurposing programs focused on one disease. Since …

Drug repositioning or repurposing is the process of discovering leading-edge indications for
authorized or declined/abandoned molecules for use in different diseases. This approach …

Parkinson's disease (PD) is a chronic progressive neurological disorder characterized by
accumulation of Lewy bodies and profound loss of substantia nigra dopaminergic neurons …

There is great unmet need in discovering novel treatment for Parkinson's disease (PD) and
identifying the new agents potentially causing drug-induced parkinsonism. New indications …

Drug development is a complex and expensive process that involves extensive research
and testing before a new drug can be approved for use. This has led to a limited availability …